EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Blimp-1 in T cells results in activation of T-bet-mediated control of immunosuppression in lung cancer

Susetta Finotto, Mircea T Chiriac, Susanne Krammer, Zuqin Yang, Laura Neurath, Carol I Geppert, Elvedina Nendel, Sonja Trump, Adriana Geiger, Stefan Wirtz, Sebastian Zundler, Markus F Neurath

Cancer Immunology, Immunotherapy · 15.04.2026 · 75 (5)

DOI: 10.1007/s00262-026-04381-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 15.04.2026. Verfasst von Susetta Finotto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pneumology, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, 91054, Erlangen, Germany. …. Hauptthemen laut MEDLINE: Positive Regulatory Domain I-Binding Factor 1, Lung Neoplasms, T-Box Domain Proteins, T-Lymphocytes, Regulatory. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Erlangen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer is the leading cause of cancer-related death in the world. Blimp-1 is a transcriptional repressor that, by interacting with other transcription factors in lymphocytes, regulates their cellular fate.

Objective

In this study, we focused on the role of Blimp-1 in T cells in lung cancer.

Methods

Here, we analyzed, in a murine model of NSCLC, the role of Blimp-1 in T cells after targeting Blimp-1 in T cells expressing lymphocyte-specific-protein tyrosine kinase (Lck), a kinase crucial for T-cell receptor signaling.

Results

We found that mice lacking Blimp1 expression in T cells have reduced lung tumor load, suppressed lung Foxp3+Treg cells in the lung and draining lymph nodes, and induced T-bet+CD4+T effector cells producing IFN-gamma and interleukin-2. Furthermore, RNA sequencing of spleen CD4+T cells showed an induction of Th1 markers, including TNF, IL-2 and interferon type I-related genes, but also PD1. RNA sequencing of spleen CD8+T cells showed induced Tc1 markers, including IL12rb1, CD44, granzyme M and eomesodermin, in the absence of Blimp1. Finally, in the lung of mice with Blimp1 deficiency in T cells, we found an upregulation of CD8+T cells with increased release of cytotoxic mediators able to induce lung tumor cell death.

Conclusions

These data indicate that the tumor microenvironment induces Blimp-1 in immunosuppressive Treg and T effector cells, thereby limiting the therapeutic efficacy of anti-tumor immune responses. Targeting of Blimp-1 in T cells emerges as a novel concept to suppress immune evasion in lung cancer by regulating CD4+, CD8+and Treg function in the lung.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positive Regulatory Domain I-Binding Factor 1Lung NeoplasmsT-Box Domain ProteinsT-Lymphocytes, RegulatoryAnimalsMiceT-bet Transcription FactorHumansImmune ToleranceMice, Inbred C57BLMice, Knockout

Stichwörter der Autor:innen

Blimp-1Granzyme MIFNIL-2LckLung CancerPD1T cellsT regulatory cellsT-bet

Substanzen

Positive Regulatory Domain I-Binding Factor 1T-Box Domain ProteinsT-bet Transcription FactorPrdm1 protein, mouse

Autor:innen und Institutionen

  • Department of Molecular Pneumology, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, 91054, Erlangen, Germany. susetta.finotto@uk-erlangen.de.
  • Deutsches Zentrum Immuntherapie (DZI), Erlangen, Germany. susetta.finotto@uk-erlangen.de.
  • Bavarian Cancer Research Center (BZKF), Erlangen, Germany. susetta.finotto@uk-erlangen.de.
  • Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. susetta.finotto@uk-erlangen.de.
  • Department of Internal Medicine 1, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
  • Department of Molecular Pneumology, Friedrich Alexander University Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, 91054, Erlangen, Germany.

Förderung

  • Universitätsklinikum Erlangen

Zitieren

APA

Finotto, S., Chiriac, M. T., Krammer, S., Yang, Z., Neurath, L., Geppert, C. I., Nendel, E., Trump, S., Geiger, A., Wirtz, S., Zundler, S., & Neurath, M. F. (2026). Targeting Blimp-1 in T cells results in activation of T-bet-mediated control of immunosuppression in lung cancer. Cancer Immunology, Immunotherapy, 75(5). https://doi.org/10.1007/s00262-026-04381-4

Vancouver

Finotto S, Chiriac MT, Krammer S, Yang Z, Neurath L, Geppert CI, et al. Targeting Blimp-1 in T cells results in activation of T-bet-mediated control of immunosuppression in lung cancer. Cancer Immunology, Immunotherapy. 2026;75(5). doi:10.1007/s00262-026-04381-4

BibTeX
@article{Finotto2026,
  author = {Finotto, Susetta and Chiriac, Mircea T and Krammer, Susanne and Yang, Zuqin and Neurath, Laura and Geppert, Carol I and Nendel, Elvedina and Trump, Sonja and Geiger, Adriana and Wirtz, Stefan and Zundler, Sebastian and Neurath, Markus F},
  title = {Targeting Blimp-1 in T cells results in activation of T-bet-mediated control of immunosuppression in lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {5},
  doi = {10.1007/s00262-026-04381-4}
}
Kostenlos starten →